Fanchen Wang

P.R. China
Zhujing, 201508, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Regulation and reversal of paclitaxel resistance via the STAT1‑mediated apoptotic pathway in ovarian cancer.

Regulation and reversal of paclitaxel resistance via the STAT1‑mediated apoptotic pathway in ovarian cancer.

Journal: International journal of oncology

Published: August 06, 2025

SLC4A11 is a targetable marker correlated with therapeutic responses in ovarian cancer.

SLC4A11 is a targetable marker correlated with therapeutic responses in ovarian cancer.

Journal: Journal of ovarian research

Published: April 29, 2025

MTA1-DT promotes endometrial cancer growth by modulating G2/M-related gene transcription via PURα.

MTA1-DT promotes endometrial cancer growth by modulating G2/M-related gene transcription via PURα.

Journal: International journal of biological macromolecules

Published: March 05, 2025

Correction: Targeting PNPO to suppress tumor growth via inhibiting autophagic flux and to reverse paclitaxel resistance in ovarian cancer.

Correction: Targeting PNPO to suppress tumor growth via inhibiting autophagic flux and to reverse paclitaxel resistance in ovarian cancer.

Journal: Apoptosis : an international journal on programmed cell death

Published: August 04, 2024

Targeting PNPO to suppress tumor growth via inhibiting autophagic flux and to reverse paclitaxel resistance in ovarian cancer.

Targeting PNPO to suppress tumor growth via inhibiting autophagic flux and to reverse paclitaxel resistance in ovarian cancer.

Journal: Apoptosis : an international journal on programmed cell death

Published: March 10, 2024

Insulin-like growth factor 2 mRNA-binding protein 2 is a therapeutic target in ovarian cancer.

Insulin-like growth factor 2 mRNA-binding protein 2 is a therapeutic target in ovarian cancer.

Journal: Experimental biology and medicine (Maywood, N.J.)

Published: December 12, 2023

Prediction Model for Therapeutic Responses in Ovarian Cancer Patients using Paclitaxel-resistant Immune-related lncRNAs.

Prediction Model for Therapeutic Responses in Ovarian Cancer Patients using Paclitaxel-resistant Immune-related lncRNAs.

Journal: Current medicinal chemistry

Published: September 09, 2023

Cyclin dependent kinase 14 as a paclitaxel-resistant marker regulated by the TGF-β signaling pathway in human ovarian cancer.

Cyclin dependent kinase 14 as a paclitaxel-resistant marker regulated by the TGF-β signaling pathway in human ovarian cancer.

Journal: Journal of Cancer

Published: June 06, 2023

RBM15‑mediating MDR1 mRNA m6A methylation regulated by the TGF‑β signaling pathway in paclitaxel‑resistant ovarian cancer.

RBM15‑mediating MDR1 mRNA m6A methylation regulated by the TGF‑β signaling pathway in paclitaxel‑resistant ovarian cancer.

Journal: International journal of oncology

Published: April 05, 2023

Protoporphyrin IX-loaded albumin nanoparticles reverse cancer chemoresistance by enhancing intracellular reactive oxygen species.

Protoporphyrin IX-loaded albumin nanoparticles reverse cancer chemoresistance by enhancing intracellular reactive oxygen species.

Journal: Nanomedicine : nanotechnology, biology, and medicine

Published: September 26, 2022

Target Finder of Transcription Factor (TFoTF): a novel tool to predict transcription factor-targeted genes in cancer.

Target Finder of Transcription Factor (TFoTF): a novel tool to predict transcription factor-targeted genes in cancer.

Journal: Molecular oncology

Published: May 04, 2022

Lipid-coated albumin-paclitaxel nanoparticles loaded with sorcin-siRNA reverse cancer chemoresistance via restoring intracellular calcium ion homeostasis.

Lipid-coated albumin-paclitaxel nanoparticles loaded with sorcin-siRNA reverse cancer chemoresistance via restoring intracellular calcium ion homeostasis.

Journal: Journal of nanobiotechnology

Published: April 01, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026